Nafamostat mesylate NEW
| Price | $39 | $62 | $89 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Nafamostat mesylate | CAS No.: 82956-11-4 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Nafamostat mesylate |
| Description | Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
| In vitro | Nafamostat Mesylate inhibits both the activation of NF-κB and apoptosis induced by gemcitabine and restrains the growth of pancreatic tumors. At a dosage of 10 mg/kg, it exhibits an inhibitory effect on wounds induced by trypsin. Furthermore, at the same dosage, Nafamostat Mesylate suppresses tryptase activity in mouse skin. |
| In vivo | Nafamostat mesilate significantly inhibits the release of platelet β-thromboglobulin (βTG) and the release of elastase from neutrophils. It also prevents the formation of complexes between the C1 inhibitor and both prekallikrein and FXIIa. Furthermore, Nafamostat mesilate inhibits the extrinsic pathway activity mediated by the TF-F.VIIa complex, leading to the production of F.Xa, with an IC50 value of 0.1 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (83.4 mM) H2O : 54 mg/mL (100 mM) |
| Keywords | Threonine proteases | FUT175 | Apoptosis | Serine endopeptidases | SARS-CoV | Ser/Thr Protease | SARS coronavirus | Serine proteases | Nafamostat mesylate | Nafamostat Mesylate | Inhibitor | inhibit | FUT 175 | Nafamostat |
| Inhibitors Related | Stavudine | Hydroxychloroquine | Tributyrin |
| Related Compound Libraries | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $100.00/1G |
VIP3Y
|
Hebei Dangtong Import and export Co LTD
|
2024-09-10 | |
| $0.00/1Kg |
VIP1Y
|
airuikechemical co., ltd.
|
2024-04-10 | |
| $0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-04-01 | |
| $30.00/1kg |
Anhui Ruihan Technology Co., Ltd
|
2023-08-16 | ||
| $0.00/100g |
Anhui Zhongda Biotechnology Co., Ltd
|
2023-08-14 | ||
| $90.00/1kg |
Anhui Zhongda Biotechnology Co., Ltd
|
2023-08-11 | ||
| $0.00/25KG |
Shandong Huisheng Import & Export Co., Ltd.
|
2023-08-10 | ||
| $200.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-06-19 | ||
| $100.00/1kg |
Shanghai Quedan biology science and technology co., ltd
|
2022-10-31 | ||
| $100.00/25kg |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2022-07-04 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY